Dose of desferrioxamine and evolution of HIV‐1 infection in thalassaemic patients
The DOI matches its Crossref record.
Abstract
Summary: To study the relationship between the dose of desferrioxamine (DFX) and the progression of the HIV‐1 disease in thalassaemia major patients (TMP), 64 seropositive TMP patients were studied. Cumulative incidence of CDC stage IV was calculated using a non‐parametric life‐table method. The association with the mean daily dose of DFX was tested with a Cox proportional hazards model which was also used to adjust for confounding variables. The median of the mean daily dose of DFX over the seropositive period was 40mg/kg (range 0‐65mg/kg). Age at seroconversion (P < 0.02) and splenectomy (P < 0.03) were found to be associated with the mean daily dose of DFX. 6.5 years after seroconversion, 11% of those who had been prescribed more than 40mg/kg of DFX daily had entered stage IV versus 35% of those who had been prescribed a lower dose (P < 0.01). When the dose was taken as a continuous variable it was found that the rate of progression was significantly smaller in TMP receiving a higher dose (P < 0.002). even after adjusting for age and splenectomy (P < 0.02). Although it should be noted that these results were obtained in an observational study, possibly biased by a non‐random allocation of the DFX dose, we believe that they are striking enough to support the claim that the role of DFX in the progression of HIV disease should be further evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Viral infection and iron metabolism
Drakesmith, H., & Prentice, A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1930 · Cited by 469
Host-Pathogen Interactions: The Role of Iron1,
Doherty, C. P. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.5.1341 · Cited by 186
“In iron-overloaded thalassemia major patients infected with HIV, the rate of progression of HIV disease was significantly associated with lower doses of desferroxamine and higher serum ferritin concentrations (39).”
BackgroundIron status and the outcome of HIV infection: an overview
Gordeuk, V. R., Delanghe, J. R., Langlois, M. R., & Boelaert, J. R. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00134-7 · Cited by 124
Bone marrow macrophage iron grade and survival of HIV-seropositive patients
de Monyé, C., Karcher, D. S., Boelaert, J. R., & Gordeuk, V. R. (1999) · AIDS · doi:10.1097/00002030-199902250-00010 · Cited by 112
Effect of transfusional iron overload on immune response.
Cunningham‐Rundles, S., Giardina, P. J., Grady, R. W., Califano, C., McKenzie, P., & De Sousa, M. (2000) · The Journal of Infectious Diseases · doi:10.1086/315919 · Cited by 71
Metadata
- Authors
- Costagliola, D. G., Montalembert, M. D., Lefrère, J., Briand, C., Rebulla, P., Baruchel, S., Dessi, C., Fondu, P., Karagiorga, M., Perrimond, H., & Girot, R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 1994-08
- Volume
- 87
- Issue
- 4
- Pages
- 849-852
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2000755913
- Cited by
- 50
- References
- 0
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose of desferrioxamine and evolution of HIV‐1 infection in thalassaemic patients. https://app.cochat.ai/papers/10.1111/j.1365-2141.1994.tb06750.x
- The paper
- Costagliola, D. G., Montalembert, M. D., Lefrère, J., Briand, C., Rebulla, P., Baruchel, S., Dessi, C., Fondu, P., Karagiorga, M., Perrimond, H., & Girot, R. (1994). Dose of desferrioxamine and evolution of HIV‐1 infection in thalassaemic patients. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.1994.tb06750.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.